Use of clinical and treatment factors to predict survival outcome in nonmetastatic metaplastic breast cancer.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 11-11 ◽  
Author(s):  
L. L. Lai ◽  
T. H. Luu ◽  
R. A. Nelson
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Breast Cancer Subtype ◽  
Tumor Grade ◽  
Molecular Data ◽  
Rank Test ◽  
Metaplastic Breast Cancer ◽  
Chi Square ◽  
Cancer Data ◽  
Cancer Subtype

11 Background: Although metaplastic breast cancer (MBC) represents < 1% of breast cancer, stem cell research has stimulated interest in the genetics and biology of MBC. Because prognostic clinical and treatment factors remain ill-defined for this rare breast cancer subtype, we queried a public cancer data registry to identify factors predictive of overall survival (OS) in MBC. Methods: Patients diagnosed with breast cancer from 2001-2008 were identified using the Surveillance, Epidemiology, and End Results (SEER) database. We included only patients with infiltrating ductal carcinoma (IDC) and MBC who had non-metastatic disease. Patients were evaluated by standard demographic, clinicopathologic, and treatment factors including age, race/ethnicity, extent of disease, tumor marker expression and treatment received. Differences between IDC and MBC were assessed using Chi-Square methods. OS across groups was measured using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazard and stepwise models were used to identify prognostic variables and to adjust for covariates. Median follow-up was 31 months. Results: Of the total 508,071 breast cancer cases, there were 1,246 (0.25%) patients with MBC and 392,809 (77%) with IDC. 5-yr OS for locoregional MBC and IDC was 67% and 84%, respectively (p<0.0001). When compared with IDC, MBC patients were older, had larger ER/PR negative cancers, and were more likely to have nodal disease. Factors predictive of worse OS in MBC on multivariate analysis are listed below. Tumor grade, ER/PR expression, and type of surgery (partial v. total mastectomy) did not impact OS. Of the treatment factors, only radiation affected OS (p=0.0002). Conclusions: To our knowledge this is the largest report of clinical and treatment factors predictive of outcomes in patients with MBC. Studies integrating clinical factors with molecular data may advance therapy that is more specific for this rare breast cancer subtype. [Table: see text]

Primary gynecological neoplasms and clinical outcomes in patients diagnosed with breast carcinoma

2006 ◽  
Vol 16 (Suppl 1) ◽  
pp. 118-122
Author(s):  
P. F. Escobar ◽  
R. Patrick ◽  
L. Rybicki ◽  
N. Al-Husaini ◽  
C. M. Michener ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcomes ◽  
Cancer Diagnosis ◽  
Ductal Carcinoma ◽  
Bilateral Breast Cancer ◽  
Breast Cancer Diagnosis ◽  
Rank Test ◽  
Cancer Data ◽  
Synchronous Bilateral Breast Cancer ◽  
Gynecological Neoplasms

The purpose of this study was to quantify and describe nonmammary neoplasms (n-MN), particularly gynecological neoplasms, in a patient population previously diagnosed with breast cancer. Data were collected prospectively in our institutional review board–approved registry for patients diagnosed with infiltrating breast cancer or ductal carcinoma in situ. Patients who developed a second, n-MN were identified; neoplastic site, time to development after breast cancer, and clinical outcomes were recorded. FIGO stage was recorded for patients who developed a gynecological neoplasm. Synchronous bilateral breast cancer was defined as a second, contralateral diagnosis made within 12 months of the first and, similarly, synchronous n-MN were defined as those identified within 1 year of a breast cancer diagnosis. Outcome curves were generated using the method of Kaplan and Meier, and compared using the log-rank test. Of 4126 patients diagnosed with breast cancer, 3% developed a n-MN, the majority of which were nongynecological and asynchronous to the initial breast cancer diagnosis. Three percent of patients diagnosed with breast cancer were diagnosed with a second, n-MN. Among patients who developed a n-MN, most developed a nongynecological cancer more than 1 year after the initial breast cancer diagnosis, and their outcomes were significantly worse than those patients who did not develop a n-MN.

scholarly journals A Cascade Deep Forest Model for Breast Cancer Subtype Classification Using Multi-Omics Data

Mathematics ◽  
2021 ◽  
Vol 9 (13) ◽  
pp. 1574
Author(s):  
Ala’a El-Nabawy ◽  
Nahla A. Belal ◽  
Nashwa El-Bendary
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtype ◽  
Biological Data ◽  
Cancer Subtypes ◽  
Cancer Data ◽  
Subtype Classification ◽  
Computational Performance ◽  
Cancer Subtype ◽  
Deep Forest ◽  
Single Data

Automated diagnosis systems aim to reduce the cost of diagnosis while maintaining the same efficiency. Many methods have been used for breast cancer subtype classification. Some use single data source, while others integrate many data sources, the case that results in reduced computational performance as opposed to accuracy. Breast cancer data, especially biological data, is known for its imbalance, with lack of extensive amounts of histopathological images as biological data. Recent studies have shown that cascade Deep Forest ensemble model achieves a competitive classification accuracy compared with other alternatives, such as the general ensemble learning methods and the conventional deep neural networks (DNNs), especially for imbalanced training sets, through learning hyper-representations through using cascade ensemble decision trees. In this work, a cascade Deep Forest is employed to classify breast cancer subtypes, IntClust and Pam50, using multi-omics datasets and different configurations. The results obtained recorded an accuracy of 83.45% for 5 subtypes and 77.55% for 10 subtypes. The significance of this work is that it is shown that using gene expression data alone with the cascade Deep Forest classifier achieves comparable accuracy to other techniques with higher computational performance, where the time recorded is about 5 s for 10 subtypes, and 7 s for 5 subtypes.

Receptor tyrosine kinase gene amplification is predictive of intraoperative seizures during glioma resection with functional mapping

2020 ◽  
Vol 132 (4) ◽  
pp. 1017-1023 ◽  
Author(s):  
Bryan D. Choi ◽  
Daniel K. Lee ◽  
Jimmy C. Yang ◽  
Caroline M. Ayinon ◽  
Christine K. Lee ◽  
...  
Keyword(s):  
Tyrosine Kinases ◽  
Univariate Analysis ◽  
Tumor Resection ◽  
Tumor Grade ◽  
Molecular Data ◽  
Genetic Alterations ◽  
Functional Mapping ◽  
Chi Square ◽  
Kinase Gene ◽  
Glioma Resection

OBJECTIVEIntraoperative seizures during craniotomy with functional mapping is a common complication that impedes optimal tumor resection and results in significant morbidity. The relationship between genetic mutations in gliomas and the incidence of intraoperative seizures has not been well characterized. Here, the authors performed a retrospective study of patients treated at their institution over the last 12 years to determine whether molecular data can be used to predict the incidence of this complication.METHODSThe authors queried their institutional database for patients with brain tumors who underwent resection with intraoperative functional mapping between 2005 and 2017. Basic clinicopathological characteristics, including the status of the following genes, were recorded: IDH1/2, PIK3CA, BRAF, KRAS, AKT1, EGFR, PDGFRA, MET, MGMT, and 1p/19q. Relationships between gene alterations and intraoperative seizures were evaluated using chi-square and two-sample t-test univariate analysis. When considering multiple predictive factors, a logistic multivariate approach was taken.RESULTSOverall, 416 patients met criteria for inclusion; of these patients, 98 (24%) experienced an intraoperative seizure. Patients with a history of preoperative seizure and those treated with antiepileptic drugs prior to surgery were less likely to have intraoperative seizures (history: OR 0.61 [95% CI 0.38–0.96], chi-square = 4.65, p = 0.03; AED load: OR 0.46 [95% CI 0.26–0.80], chi-square = 7.64, p = 0.01). In a univariate analysis of genetic markers, amplification of genes encoding receptor tyrosine kinases (RTKs) was specifically identified as a positive predictor of seizures (OR 5.47 [95% CI 1.22–24.47], chi-square = 5.98, p = 0.01). In multivariate analyses considering RTK status, AED use, and either 2007 WHO tumor grade or modern 2016 WHO tumor groups, the authors found that amplification of the RTK proto-oncogene, MET, was most predictive of intraoperative seizure (p < 0.05).CONCLUSIONSThis study describes a previously unreported association between genetic alterations in RTKs and the occurrence of intraoperative seizures during glioma resection with functional mapping. Future models estimating intraoperative seizure risk may be enhanced by inclusion of genetic criteria.

scholarly journals Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dechuang Jiao ◽  
Jingyang Zhang ◽  
Jiujun Zhu ◽  
Xuhui Guo ◽  
Yue Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cox Model ◽  
Survival Rates ◽  
Tumor Grade ◽  
Population Based ◽  
Rank Test ◽  
Breast Cancers ◽  
Significant Independent Predictor ◽  
Cancer Specific Survival ◽  
7Th Edition

Abstract Background Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. Methods Surveillance, Epidemiology, and End Results (SEER) database was searched to identify cases with confirmed non-metastatic IBC and T4-non-IBC who had received surgery, chemotherapy, and radiotherapy between 2010 and 2015. IBC was defined as per the American Joint Committee on Cancer (AJCC) 7th edition. Breast Cancer-Specific Survival (BCSS) was estimated by plotting the Kaplan-Meier curve and compared across groups by using the log-rank test. Cox model was constructed to determine the association between IBC and BCSS after adjusting for age, race, stage of disease, tumor grade and surgery type. Results Out of a total of 1986 patients, 37.1% had IBC and mean age was 56.6 ± 12.4. After a median follow-up time of 28 months, 3-year BCSS rate for IBC and T4-non-IBC patients was 81.4 and 81.9%, respectively (log-rank p = 0.398). The 3-year BCSS rate in HR−/HER2+ cohort was higher for IBC patients than T4-non-IBC patients (89.5% vs. 80.8%; log-rank p = 0.028), and in HR−/HER2- cohort it was significantly lower for IBC patients than T4-non-IBC patients (57.4% vs. 67.5%; log-rank p = 0.010). However, it was identical between IBC and T4-non-IBC patients in both HR+/HER2- (85.0% vs. 85.3%; log-rank p = 0.567) and HR+/HER2+ (93.6% vs. 91.0%, log-rank p = 0.510) cohorts. After adjusting for potential confounding variables, we observed that IBC is a significant independent predictor for survival of HR−/HER2+ cohort (hazards ratio [HR] = 0.442; 95% CI: 0.216–0.902; P = 0.025) and HR−/HER2- cohort (HR = 1.738; 95% CI: 1.192–2.534; P = 0.004). Conclusions Patients with IBC and T4-non-IBC had a similar BCSS in the era of modern systemic treatment. In IBC patients, the HR−/HER2+ subtype is associated with a better outcome, and HR−/HER2- subtype is associated with poorer outcomes as compared to the T4-non-IBC patients.

scholarly journals High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer

2019 ◽  
Vol 106 (1) ◽  
pp. 64-69
Author(s):  
Massimiliano Gennaro ◽  
Elisabetta Meneghini ◽  
Paolo Baili ◽  
Sara Bravaccini ◽  
Annalisa Curcio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Active Surveillance ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Tumor Grade ◽  
Receptor Expression ◽  
Invasive Cancer ◽  
Her2 Positive ◽  
Hormone Receptor Expression ◽  
High Consistency

Background: Ductal carcinoma in situ (DCIS) is considered a morphologic precursor of invasive cancer and is often treated with adjuvant whole-breast irradiation and endocrine therapy, as if it were an invasive cancer. Our aim was to provide further support for treatment de-escalation or enrollment of such patients in active surveillance trials. Methods: We retrospectively analyzed data on patients with conservatively treated primary DCIS subsequently diagnosed with ipsilateral invasive breast cancer (IBC) at 2 comprehensive breast cancer centers. From their merged databases, we identified 50 cases with full details on tumor grade, hormone receptor expression, and HER2 amplification, for both the primary DCIS and the corresponding IBC, and we assessed the similarities and differences between the two. Results: Distributions of hormone receptors were similar in primary DCIS and IBC, while high-grade and HER2-positive status was less common in IBC than in primary DCIS. The positivity for estrogen receptors (ER) and well-differentiated or moderately differentiated morphology in the primary DCIS persisted in 90% of the matching IBC. Changes in progesterone receptor expression were slightly more common than those in ER expression. Overall consistency for the luminal-like receptors subtype was found in 90% of cases. Conclusion: The high consistency between the features of primary DCIS and those of subsequent IBC (in the rare but not negligible cases of local failure) should be borne in mind when considering the therapeutic options. Treatment de-escalation and accrual of patients for active surveillance trials could be appropriate for luminal-like precursors.

scholarly journals Erratum to: Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women

2017 ◽  
Vol 166 (1) ◽  
pp. 195-195 ◽  
Author(s):  
María Elena Martínez ◽  
Scarlett L. Gomez ◽  
Li Tao ◽  
Rosemary Cress ◽  
Danielle Rodriguez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Socioeconomic Factors ◽  
White Women ◽  
Breast Cancer Subtype ◽  
Cancer Subtype ◽  
Hispanic White

scholarly journals Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer

2010 ◽  
Vol 1 (5) ◽  
pp. 747-754 ◽  
Author(s):  
REIKI NISHIMURA ◽  
TOMOFUMI OSAKO ◽  
YASUHIRO OKUMURA ◽  
MITSUHIRO HAYASHI ◽  
YASUO TOYOZUMI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Primary Breast Cancer ◽  
Breast Cancer Subtype ◽  
Recurrence Time ◽  
Ki 67 ◽  
Cancer Subtype

Predictors of receiving survivorship care plans and visits.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12055-12055
Author(s):  
Christine M. Duffy ◽  
Harish Saiganesh ◽  
Stavroula Chrysanthopoulou ◽  
Camille Higel-Mcgovern ◽  
Don S. Dizon
Keyword(s):  
Breast Cancer ◽  
Stage Iv ◽  
Rank Test ◽  
Survivorship Care Plans ◽  
Survivorship Care ◽  
Clinical Predictors ◽  
Chi Square ◽  
Logistic Regression Models ◽  
Care Plans ◽  
Stage Iv Disease

12055 Background: While the Commission on Cancer has eliminated strict quotas for accreditation, Survivorship Care Plans (SCPs) and/or Survivorship Care Visits (SCV) at treatment completion are encouraged. However, who receives a SCP or SCV, whether it impacts care, and impact of distress on care is unknown. We examined the provision of survivorship care at the Lifespan Cancer Institute (LCI) to determine (1) clinical and distress thermometer scores (DTS) association with SCPs and SCVs; (2) impact of SCV visits on specialty referrals, and (3) demographic and clinical predictors of receipt of SCP and SCV. Methods: We retrospectively reviewed EMR records on 1,960 patients at LCI between 2014-2017 for SCPs and SCVs and extracted demographics, treatment variables, and distress scores. We used T-test or Wilcoxon rank test and Chi-square tests for evaluating the bivariate associations of SCP and SCV with continuous and categorical factors respectively. We fit logistic regression models to assess the adjusted effect of these factors on receipt of SCP and SCV independently. All analyses were performed in R v4.0.2. Results: The mean age was 63.9 (SD=11.8), 67% were female, 51.2% were married or partnered. Breast (38.8%), lung (17.6%), and prostate (13.7%) were the most common cancers. DTS were recorded in 64% with mean of 3.88(SD=3.05): distress was higher in women (4.36, SD=3.01), breast cancer pts (4.53, SD=3.07), gyn (4.22, SD=3.07), pancreatic (4.12, SD=3.41) and anal cancers (4.52, SD=3.47) and in those with Stage IV disease (5.33, SD=3.43). SCPs were completed in 740 (37.8%) patients and of those 65.9% had a SCV. SCV were associated with more specialty referrals for psychiatry, physical therapy, nutrition, and sexual health but not smoking cessation or fiscal services. DTS were associated with increased referral to psychiatry only. The adjusted models (table) showed odds of receiving a SCP were higher in those younger, and having breast cancer v all other cancers, with prostate having lowest odds. For receipt of SCV, odds were higher in those younger, female, and having breast cancer, with prostate and lung having the lowest odds. Conclusions: Gender, age and type of cancer are significant predictors of receipt of SCP and SCV. SCP and SCV patterns may represent patient preferences, but practice patterns and unconscious biases may also play a part suggesting areas for further research and outreach.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document